Search

Your search keyword '"Mariappan, Paramananthan"' showing total 216 results
Start Over Author "Mariappan, Paramananthan"
216 results on '"Mariappan, Paramananthan"'

1. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update

Author

Gontero, Paolo, Birtle, Alison, Capoun, Otakar, Compérat, Eva, Dominguez-Escrig, José L., Liedberg, Fredrik, Mariappan, Paramananthan, Masson-Lecomte, Alexandra, Mostafid, Hugh A., Pradere, Benjamin, Rai, Bhavan P., van Rhijn, Bas W.G., Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Wood, Robert, and Xylinas, Evanguelos N.

Published
2024
Full Text
View/download PDF

2. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

Author

Li, Roger, Hensley, Patrick J., Gupta, Shilpa, Al-Ahmadie, Hikmat, Babjuk, Marko, Black, Peter C., Brausi, Maurizio, Bree, Kelly K., Fernández, Mario I., Guo, Charles C., Horowitz, Amir, Lamm, Donald L., Lerner, Seth P., Lotan, Yair, Mariappan, Paramananthan, McConkey, David, Mertens, Laura S., Mir, Carmen, Ross, Jeffrey S., O’Donnell, Michael, Palou, Joan, Pohar, Kamal, Steinberg, Gary, Soloway, Mark, Spiess, Philippe E., Svatek, Robert S., Tan, Wei Shen, Taoka, Rikiya, Buckley, Roger, and Kamat, Ashish M.

Published
2024
Full Text
View/download PDF

3. Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non–muscle-invasive Bladder Cancer

Author

Mariappan, Paramananthan, Johnston, Allan, Trail, Matthew, Hamid, Sami, Hollins, Graham, Dreyer, Barend A., Ramsey, Sara, Padovani, Luisa, Garau, Roberta, Enriquez, Julia Guerrero, Boden, Alasdair, Maresca, Gianluca, Simpson, Helen, Hasan, Rami, Sharpe, Claire, Thomas, Benjamin G., Chaudhry, Altaf H., Khan, Rehan S., Bhatt, Jaimin R., Ahmad, Imran, Nandwani, Ghulam M., Dimitropoulos, Konstantinos, Makaroff, Lydia, Shaw, Johnstone, Graham, Catriona, and Hendry, David

Published
2024
Full Text
View/download PDF

6. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

Author

Mertens, Laura S., Bruins, Harman Maxim, Contieri, Roberto, Babjuk, Marek, Rai, Bhavan P., Puig, Albert Carrión, Escrig, Jose Luis Dominguez, Gontero, Paolo, van der Heijden, Antoine G., Liedberg, Fredrik, Martini, Alberto, Masson-Lecomte, Alexandra, Meijer, Richard P., Mostafid, Hugh, Neuzillet, Yann, Pradere, Benjamin, Redlef, John, van Rhijn, Bas W.G., Rouanne, Matthieu, Rouprêt, Morgan, Sæbjørnsen, Sæbjørn, Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Thalmann, George, Xylinas, Evanguelos, Mariappan, Paramananthan, and Alfred Witjes, J.

Published
2024
Full Text
View/download PDF

8. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Author

Rouprêt, Morgan, Seisen, Thomas, Birtle, Alison J., Capoun, Otakar, Compérat, Eva M., Dominguez-Escrig, José L., Gürses Andersson, Irene, Liedberg, Fredrik, Mariappan, Paramananthan, Hugh Mostafid, A., Pradere, Benjamin, van Rhijn, Bas W.G., Shariat, Shahrokh F., Rai, Bhavan P., Soria, Francesco, Soukup, Viktor, Wood, Robbert G., Xylinas, Evanguelos N., Masson-Lecomte, Alexandra, and Gontero, Paolo

Published
2023
Full Text
View/download PDF

9. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial

Author

Tan, Wei Shen, Prendergast, Aaron, Ackerman, Charlotte, Yogeswaran, Yathushan, Cresswell, Joanne, Mariappan, Paramananthan, Phull, Jaspal, Hunter-Campbell, Paul, Lazarowicz, Henry, Mishra, Vibhash, Rane, Abhay, Davies, Melissa, Warburton, Hazel, Cooke, Peter, Mostafid, Hugh, Wilby, Daniel, Mills, Robert, Issa, Rami, and Kelly, John D.

Published
2023
Full Text
View/download PDF

10. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

Author

Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed Musa, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kondža, Andraž, Barcelos, André, Galosi, Andrea Benedetto, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, de Jalón, Ángel García, Desai, Ankit, Czech, Anna Katarzyna, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Lal, Asim Ahmed, Yıldırım, Asıf, Voulgaris, Athanasios Marios, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, Chi-Fai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Plaza Alonso, Cristina, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Hrouda, David, Lau, David Hua Wu, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Canelon Castillo, Elba, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, MacLennan, Graeme, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Rios Pita, Hernado, Clarke, Holly, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Koo, Hui Fen, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomašković, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D., Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy Yuen-Chun, Iacovou, John, Kelly, John, Selph, John P., Aning, Jonathan, Deeks, Jon, Cobley, Jonathan, Olivier, Jonathan, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Gillams, Kathryn, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Antón-Juanilla, Marta, Rivero, Marta Viridiana Muñoz, Pirša, Matea, Tallè, Matteo, Crockett, Matthew, Liew, Matthew, Trail, Matthew, Peters, Max, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akalın, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al-Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Oteo Manjavacas, Pablo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C., Osei-Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L., Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P., Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Mohammud Inder, Shakeel, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Grzegorz Kata, Slawomir, Pinheiro Lopes, Sofia, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Shahzad, Yan, Sylvia, Lee, Taeweon, Uçar, Taha, Drake, Tamsin, Toma, Tarq, Cabañuz Plo, Teresa, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Tomaž, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çaşkurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Parejo Cortes, Victor, Capapé Poves, Victoria, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Fung Chin, Yew, Filtekin, Yigit, Chyn Phan, Yih, Ibrahim, Youssed, Glaser, Zachary A, Abiddin, Zainal Adwin, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli, Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Anbarasan, Thineskrishna, Mannas, Miles P., Marra, Giancarlo, Gómez Rivas, Juan, Marcq, Gautier, Assmus, Mark A., Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Boxall, Nicholas E., Downey, Alison P., Sukhu, Troy A., Chin, Yew-Fung, Green, James S.A., Goulao, Beatriz, Nielsen, Matthew, McGrath, John S., and Kasivisvanathan, Veeru

Published
2022
Full Text
View/download PDF

11. Quality of bladder cancer surgery : improving outcomes

Author

Mariappan, Paramananthan

Subjects
616.99, urinary bladder cancer, NMIBC, cystoscopy, quality of life, pattern of recurrence, TURBT, Good Quality White Light TURBT, GQ-WLTURBT, photodynamic diagnosis, international guidelines
Abstract

Background: At the time of diagnosis, approximately 75% of all bladder cancers are Non-Muscle Invasive Bladder Cancers (NMIBC) - the standard treatment for these cancers is a Transurethral Resection of the Bladder Tumour (TURBT). Although, the vast majority of these cancers are not life-threatening, they have a high risk of recurrence (and progression, particularly in higher risk NMIBC), despite the use of adjuvant intravesical chemotherapy. Consequently, patients are kept on long term cystoscopic surveillance with endoscopic removal if recurrences are detected - this impacts on patients' quality of life and contributes to the high cost for the healthcare provider. Aims: The fundamental aim of this series of clinical studies, spanning 12 years, was to identify and implement, means of improving the efficiency in both processing and operating on patients with NMIBC to not only reduce recurrence, but also to reduce the duration of follow up and repeat operations. It was an evolutionary process where the findings in the preceding studies formed the basis of the subsequent one - while the aim of the individual studies were different, there was a clear link to the essential principles, thus forming a coherent collection of studies. Methods and results: The project was carried out in 3 phases (with 2 or 3 main studies in each phase, augmented by 1 to 2 linked studies - making the entire submission for PhD by publications a series of 12 studies, to date): Phase 1 (5 studies in this phase): The aim was to demonstrate the natural history of non-invasive bladder cancer and identify sub-categories of patients who could be discharged from surveillance at 5 years. This was initially achieved by evaluating a prospectively maintained cohort of non-invasive bladder cancer patients diagnosed between 1978 and 1984 at the Western General Hospital, Edinburgh. This study identified the importance of the recurrence rate at the first follow up cystoscopy (RRFFC) as an essential prognostic marker. This finding was further validated using 2 separate cohorts from a different Centre (the Royal Infirmary, Edinburgh) managed in the 80s and the 90s, respectively. The data confirmed that over the decades, recurrence patterns do change, possibly as a result of differing techniques and improvements in optics and instruments; however, what remained the same was the prognostic value of the RRFFC. Phase 2 (3 studies in this phase): The early recurrence was deemed to be the result of missed and tumours left behind at the initial TURBT, i.e. a marker of quality. However, RRFFC was only known 3 months after the initial surgery. Since the RRFFC was such an important prognostic factor, the aim of this phase was to determine the surgical factors contributing to the quality of TURBT and subsequently implement changes to the principles in carrying out the surgery to improve this quality. This was achieved by prospective collection of information regarding all patients undergoing TURBT for new bladder cancers, recording the tumour features, surgeon experience, if the resection was deemed to have been complete or not, and the pathological results. We identified that the detrusor muscle in the resected specimen and the experience of the surgeon were independent determinants of TURBT quality. This finding was validated in a further study using cohorts from another time period and another Centre - this allowed me to develop the concept of Good Quality White Light TURBT (GQWLTURBT) as the benchmark for the white light TURBT. Phase 3 (4 studies in this phase): Photodynamic Diagnosis assisted TURBT (PDDTURBT) was demonstrated in randomised controlled trials as a technique that reduces the recurrences in NMIBC. In the absence of evidence with this technique in the 'real life' setting nor comparisons with standardised, benchmarked white light TURBT technique, we performed a prospective controlled study comparing PDD-TURBT and GQ-WLTURBT, evaluating early and delayed recurrence rates in 2 separate studies. I also performed a multicentre UK study on the outcomes with PDD-TURBT and collaborated with other experts in Europe in producing a review article around Photodynamic Diagnosis and the cost effectiveness of this technique. Summary: This coherent series of studies has contributed to knowledge in bladder cancer surgery by, among others: (a) mapping the individual patient natural history of non-invasive bladder cancer; (b) confirming the importance of early recurrence as a strong prognostic indicator; (c) identifying predictors of this early recurrence and the quality of TURBT; (d) introducing the concept of the benchmark Good Quality White Light TURBT and (e) demonstrating the benefits of photodynamic diagnosis within a 'real life' setting.

Published
2018

12. National audit of patient reported experience of radical cystectomy for bladder cancer pathways.

Author

Kuppanda, Preksha, Hermans, Louisa, Uren, Alan, Cotterill, Nikki, Rowe, Edward, Narahari, Krishna, Dickinson, Andrew, Rigby, Jeannie, Aning, Jonathan, Calleja, Edward, Perry, Matthew, Abdulmajed, Mohamed, Dawam, Daben, Karanjia, Rustam, John, Joseph, Colquhoun, Alexandra, Mariappan, Paramananthan, Featherstone, Jon, Goodall, Philip, and Cooke, Pete

Published
2024
Full Text
View/download PDF

13. PD48-04 DOES ENHANCED AUDIT AND FEEDBACK WITH EDUCATION IMPROVE QUALITY INDICATOR (QI) ACHIEVEMENT AND REDUCE EARLY RECURRENCE RATES IN TURBT SURGERY FOR NMIBC? RESULTS FROM THE RESECT CLUSTER RANDOMISED TRIAL

Author

Gaba, Fortis, primary, Gallagher, Kevin, additional, Bhatt, Nikita, additional, Clement, Keiran, additional, Zimmermann, Eleanor, additional, Khadhouri, Sinan, additional, Kulkarni, Meghana, additional, Anbarasan, Thines, additional, Ng, Alexander, additional, Light, Alexander, additional, Asif, Aqua, additional, Chan, Vinson, additional, Nathan, Arjun, additional, Rossi, Sabrina, additional, Geng, Wendy, additional, Cooper, David, additional, Aucott, Lorna, additional, O’Brien, Tim, additional, MacLennan, Steven, additional, Nielsen, Matthew, additional, Mariappan, Paramananthan, additional, and Kasivisvanathan, Veeru, additional

Published
2024
Full Text
View/download PDF

15. The importance of being grade 3 : a plea for a three-tier hybrid classification system for grade in primary non–muscle-invasive bladder cancer

Author

Beijert, Irene J., Hagberg, Oskar, Gårdmark, Truls, Holmberg, Lars, Häggström, Christel, Johnston, Allan, Trail, Matthew, Hamid, Sami, Dreyer, Barend A., Padovani, Luisa, Garau, Roberta, Hasan, Rami, Ahmad, Imran, Hendry, David, Compérat, Eva M., Burger, Maximilian, Rouprêt, Morgan, Gontero, Paolo, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., Mariappan, Paramananthan, Liedberg, Fredrik, van Rhijn, Bas W.G., Beijert, Irene J., Hagberg, Oskar, Gårdmark, Truls, Holmberg, Lars, Häggström, Christel, Johnston, Allan, Trail, Matthew, Hamid, Sami, Dreyer, Barend A., Padovani, Luisa, Garau, Roberta, Hasan, Rami, Ahmad, Imran, Hendry, David, Compérat, Eva M., Burger, Maximilian, Rouprêt, Morgan, Gontero, Paolo, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., Mariappan, Paramananthan, Liedberg, Fredrik, and van Rhijn, Bas W.G.

Abstract

Grade is an important determinant of progression in non–muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1: hazard ratio [HR] = 1.92; cohort 2: HR = 2.51, and cohort 3: HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers.

Published
2024
Full Text
View/download PDF

16. Corrigendum to 'European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31, (S0302283823030737), (10.1016/j.eururo.2023.08.016)]

Author

MS Urologische Oncologie, Cancer, Alfred Witjes, J, Bruins, Harman Max, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebiaco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, Mariappan, Paramananthan, van der Heijden, Antoine G, MS Urologische Oncologie, Cancer, Alfred Witjes, J, Bruins, Harman Max, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A, Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S, Meijer, Richard P, Milowsky, Matthew I, Neuzillet, Yann, Panebiaco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N, Sæbjørnsen, Sæbjørn, Veskimäe, Erik, Mariappan, Paramananthan, and van der Heijden, Antoine G

Published
2024

17. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non–muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland’s Quality Performance Indicators Programme

Author

Mariappan, Paramananthan, Johnston, Allan, Padovani, Luisa, Clark, Eilidh, Trail, Matthew, Hamid, Sami, Hollins, Graham, Simpson, Helen, Thomas, Benjamin G., Hasan, Rami, Bhatt, Jaimin, Ahmad, Imran, Nandwani, Ghulam M., Mitchell, Ian D.C., and Hendry, David

Published
2020
Full Text
View/download PDF

18. Corrigendum to “European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31]

Author

Alfred Witjes, J., primary, Bruins, Harman Max, additional, Carrión, Albert, additional, Cathomas, Richard, additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Fietkau, Rainer, additional, Gakis, Georgios, additional, Lorch, Anja, additional, Martini, Alberto, additional, Mertens, Laura S., additional, Meijer, Richard P., additional, Milowsky, Matthew I., additional, Neuzillet, Yann, additional, Panebiaco, Valeria, additional, Redlef, John, additional, Rink, Michael, additional, Rouanne, Mathieu, additional, Thalmann, George N., additional, Sæbjørnsen, Sæbjørn, additional, Veskimäe, Erik, additional, Mariappan, Paramananthan, additional, and van der Heijden, Antoine G., additional

Published
2024
Full Text
View/download PDF

20. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

Author

Monteiro, Leonardo L., Witjes, J. Alfred, Agarwal, Piyush K., Anderson, Christopher B., Bivalacqua, Trinity J., Bochner, Bernard H., Boormans, Joost L., Chang, Sam S., Domínguez-Escrig, Jose L., McKiernan, James M., Dinney, Colin, Godoy, Guilherme, Kulkarni, Girish S., Mariappan, Paramananthan, O’Donnell, Michael A., Rentsch, Cyrill A., Shah, Jay B., Solsona, Eduardo, Svatek, Robert S., van der Heijden, Antoine G., van Valenberg, F. Johannes P., and Kassouf, Wassim

Published
2019
Full Text
View/download PDF

23. Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial

Author

Gallagher, Kevin, primary, Bhatt, Nikita, additional, Clement, Keiran, additional, Zimmermann, Eleanor, additional, Khadhouri, Sinan, additional, MacLennan, Steven, additional, Kulkarni, Meghana, additional, Gaba, Fortis, additional, Anbarasan, Thineskrishna, additional, Asif, Aqua, additional, Light, Alexander, additional, Ng, Alexander, additional, Chan, Vinson, additional, Nathan, Arjun, additional, Cooper, David, additional, Aucott, Lorna, additional, Marcq, Gautier, additional, Teoh, Jeremy Yuen-Chun, additional, Hensley, Patrick, additional, Duncan, Eilidh, additional, Goulao, Beatriz, additional, O'Brien, Tim, additional, Nielsen, Matthew, additional, Mariappan, Paramananthan, additional, and Kasivisvanathan, Veeru, additional

Published
2023
Full Text
View/download PDF

25. PD13-02 CAN EXPERIENCE OF BLUE LIGHT CYSTOSCOPY IMPROVE A SURGEON'S WHITE LIGHT RESECTION? DATA FROM THE PHOTO TRIAL

Author

Gravestock, Paul, primary, Vadiveloo, Thenmalar, additional, Lewis, Rebecca, additional, Duncan, Anne, additional, Penegar, Steven, additional, Clark, Emma, additional, Yu, Ge, additional, Mariappan, Paramananthan, additional, Cresswell, Joanne, additional, Mcgrath, John, additional, N’dow, James, additional, Nabi, Ghulam, additional, Mostafid, Hugh, additional, Kelly, John, additional, Ramsay, Craig, additional, Lazarowicz, Henry, additional, Allan, Angela, additional, Breckons, Matthew, additional, Campbell, Karen, additional, Campbell, Louise, additional, Feber, Andy, additional, Mcdonald, Alison, additional, Norrie, John, additional, Orozco-Leal, Giovany, additional, Rice, Stephen, additional, Tandogdu, Zafer, additional, Taylor, Ernest, additional, Wilson, Laura, additional, Vale, Luke, additional, Maclennan, Graeme, additional, Hall, Emma, additional, and Heer, Rakesh, additional

Published
2023
Full Text
View/download PDF

26. Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019

Author

Catto, James W F, Mandrik, Olena, Quayle, Lewis A, Hussain, Syed A, McGrath, John, Cresswell, Joanne, Birtle, Alison J, Jones, Rob J, Mariappan, Paramananthan, Makaroff, Lydia E, Knight, Allen, Mostafid, Hugh, Chilcott, Jim, Sasieni, Peter, Cumberbatch, Marcus, Catto, James W F, Mandrik, Olena, Quayle, Lewis A, Hussain, Syed A, McGrath, John, Cresswell, Joanne, Birtle, Alison J, Jones, Rob J, Mariappan, Paramananthan, Makaroff, Lydia E, Knight, Allen, Mostafid, Hugh, Chilcott, Jim, Sasieni, Peter, and Cumberbatch, Marcus

Abstract

Objective We report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral cancers from 2013 to 2019. Materials and Methods Hospital episode statistics, waiting times, and cancer registrations were extracted from NHS Digital. Results Registrations included 128 823 individuals with BC, 16 018 with UTUC, and 2533 with urethral cancer. In 2019, 150 816 persons were living with a diagnosis of BC, of whom 113 067 (75.0%) were men, 85 117 (56.5%) were aged >75 years, and 95 553 (91.7%) were Caucasian. Incidence rates were stable (32.7–34.3 for BC, 3.9–4.2 for UTUC and 0.6–0.7 for urethral cancer per 100 000 population). Most patients 52 097 (mean [range] 41.3% [40.7–42.0%]) were referred outside the 2-week-wait pathway and 15 340 (mean [range] 12.2% [11.7–12.6%]) presented as emergencies. Surgery, radiotherapy, chemotherapy, or multimodal treatment use varied with disease stage, patient factors and Cancer Alliance. Between 27% and 29% (n = 6616) of muscle-invasive BCs did not receive radical treatment. Survival rates reflected stage, grade, location, and tumour histology. Overall survival rates did not improve over time (relative change: 0.97, 95% confidence interval 0.97–0.97) at 2 years in contrast to other cancers. Conclusion The diagnostic pathway for BC needs improvement. Increases in survival might be delivered through greater use of radical treatment. NHS Digital data offers a population-wide picture of this disease but does not allow individual outcomes to be matched with disease or patient features and key parameters can be missing or incomplete.

Published
2023

27. Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019

Author

Catto, James W.F., Mandrik, Olena, Quayle, Lewis A., Hussain, Syed A., McGrath, John, Cresswell, Joanne, Birtle, Alison J, Jones, Rob J., Mariappan, Paramananthan, Makaroff, Lydia E., Knight, Allen, Mostafid, Hugh, Chilcott, Jim, Sasieni, Peter, Cumberbatch, Marcus, Catto, James W.F., Mandrik, Olena, Quayle, Lewis A., Hussain, Syed A., McGrath, John, Cresswell, Joanne, Birtle, Alison J, Jones, Rob J., Mariappan, Paramananthan, Makaroff, Lydia E., Knight, Allen, Mostafid, Hugh, Chilcott, Jim, Sasieni, Peter, and Cumberbatch, Marcus

Abstract

Objective We report NHS England data for patients with bladder cancer (BC), upper tract urothelial (UTUC: renal pelvic and ureteric) and urethral cancers from 2013 to 2019. Materials and methods Hospital episode statistics, waiting times and cancer registrations were extracted from NHS Digital. Results Registrations included 128,823 individuals with BC, 16,018 with UTUC and 2,533 with urethral cancer. In 2019, 150,816 persons were living with a diagnosis of BC, of whom 113,067 (75.0%) were men, 85,117 (56.5%) aged over 75 yrs, and 95,553 (91.7%) Caucasian. Incidence rates were stable (32.7-34.3 for BC, 3.9-4.2 for UTUC and 0.6-0.7 for urethral cancer per 100,000 population). Most patients (52,097 (41.3% (40.7-42.0%)) were referred outside the two week wait pathway and 15,340 (12.2% (11.7-12.6%)) presented as emergencies. Surgery, radiotherapy, chemotherapy or multimodal treatment use varied with disease stage, patient factors and Cancer Alliance. Between 27-29% (6,616) of muscle-invasive BCs did not receive radical treatment. Survival rates reflected stage, grade, location and tumour histology. Overall survival rates did not improve over time (relative change: 0.97 (95%CI: 0.97-0.97) at 2 years) in contrast to other cancers. Conclusion The diagnostic pathway for BC needs improvement. Increases in survival might be delivered through greater use in radical treatment. NHS Digital data offers a population-wide picture of this disease but does not allow individual outcomes to be matched with disease or patient features and key parameters can be missing or incomplete.

Published
2023

28. Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019

Author

Catto, James W.F., primary, Mandrik, Olena, additional, Quayle, Lewis A., additional, Hussain, Syed A., additional, McGrath, John, additional, Cresswell, Joanne, additional, Birtle, Alison J., additional, Jones, Rob J., additional, Mariappan, Paramananthan, additional, Makaroff, Lydia E., additional, Knight, Allen, additional, Mostafid, Hugh, additional, Chilcott, Jim, additional, Sasieni, Peter, additional, and Cumberbatch, Marcus, additional

Published
2023
Full Text
View/download PDF

29. Study protocol: transurethral REsection and Single instillation intravesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT). A multi-centre international observational study with embedded cluster randomised trial of audit, feedback and education. (Preprint)

Author

Gallagher, Kevin, primary, Bhatt, Nikita, additional, Clement, Keiran, additional, Zimmermann, Eleanor, additional, Khadhouri, Sinan, additional, MacLennan, Steven, additional, Kulkarni, Meghana, additional, Gaba, Fortis, additional, Anbarasan, Thines, additional, Asif, Aqua, additional, Light, Alexander, additional, Ng, Alexander, additional, Chan, Vinson, additional, Nathan, Arjun, additional, Cooper, David, additional, Aucott, Lorna, additional, Marcq, Gautier, additional, TEOH, Jeremy Yuen-Chun, additional, Hensley, Patrick, additional, Duncan, Eilidh, additional, Goulao, Beatrice, additional, O'Brien, Tim, additional, Nielsen, Matthew, additional, Mariappan, Paramananthan, additional, and Kasivisvanathan, Veeru, additional

Published
2023
Full Text
View/download PDF

32. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT

Author

Heer, Rakesh, primary, Lewis, Rebecca, additional, Duncan, Anne, additional, Penegar, Steven, additional, Vadiveloo, Thenmalar, additional, Clark, Emma, additional, Yu, Ge, additional, Mariappan, Paramananthan, additional, Cresswell, Joanne, additional, McGrath, John, additional, N’Dow, James, additional, Nabi, Ghulam, additional, Mostafid, Hugh, additional, Kelly, John, additional, Ramsay, Craig, additional, Lazarowicz, Henry, additional, Allan, Angela, additional, Breckons, Matthew, additional, Campbell, Karen, additional, Campbell, Louise, additional, Feber, Andy, additional, McDonald, Alison, additional, Norrie, John, additional, Orozco-Leal, Giovany, additional, Rice, Stephen, additional, Tandogdu, Zafer, additional, Taylor, Ernest, additional, Wilson, Laura, additional, Vale, Luke, additional, MacLennan, Graeme, additional, and Hall, Emma, additional

Published
2022
Full Text
View/download PDF

33. A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer

Author

Heer, Rakesh, primary, Lewis, Rebecca, additional, Vadiveloo, Thenmalar, additional, Yu, Ge, additional, Mariappan, Paramananthan, additional, Cresswell, Joanne, additional, McGrath, John, additional, Nabi, Ghulam, additional, Mostafid, Hugh, additional, Lazarowicz, Henry, additional, Kelly, John, additional, Duncan, Anne, additional, Penegar, Steven, additional, Breckons, Matt, additional, Wilson, Laura, additional, Clark, Emma, additional, Feber, Andy, additional, Orozco-Leal, Giovany, additional, Tandogdu, Zafer, additional, Taylor, Ernest, additional, N’Dow, James, additional, Norrie, John, additional, Ramsay, Craig, additional, Rice, Stephen, additional, Vale, Luke, additional, MacLennan, Graeme, additional, and Hall, Emma, additional

Published
2022
Full Text
View/download PDF

34. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial

Author

Tan, Wei Shen, primary, Prendergast, Aaron, additional, Ackerman, Charlotte, additional, Yogeswaran, Yathushan, additional, Cresswell, Joanne, additional, Mariappan, Paramananthan, additional, Phull, Jaspal, additional, Hunter-Campbell, Paul, additional, Lazarowicz, Henry, additional, Mishra, Vibhash, additional, Rane, Abhay, additional, Davies, Melissa, additional, Warburton, Hazel, additional, Cooke, Peter, additional, Mostafid, Hugh, additional, Wilby, Daniel, additional, Mills, Robert, additional, Issa, Rami, additional, and Kelly, John D., additional

Published
2022
Full Text
View/download PDF

35. Intermediate and high-risk nonmuscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.

Author

Grabe-Heyne, Kristin, Henne, Christof, Mariappan, Paramananthan, Geiges, Götz, Pöhlmann, Johannes, and Pollock, Richard F.

Subjects
BLADDER cancer, EPIDEMIOLOGY of cancer, PHYSICIAN adherence, LITERATURE reviews, CANCER invasiveness, BCG immunotherapy
Abstract

Bladder cancer ranks among the most common cancers globally. At diagnosis, 75% of patients have non-muscle-invasive bladder cancer (NMIBC). Patients with low-risk NMIBC have a good prognosis, but recurrence and progression rates remain high in intermediate- and high-risk NMIBC, despite the decades-long availability of effective treatments for NMIBC such as intravesical Bacillus Calmette-Gue'rin (BCG). The present review provides an overview of NMIBC, including its burden and treatment options, and then reviews aspects that counteract the successful treatment of NMIBC, referred to as unmet treatment needs. The scale and reasons for each unmet need are described based on a comprehensive review of the literature, including insufficient adherence to treatment guidelines by physicians because of insufficient knowledge, training, or access to certain therapy options. Low rates of lifestyle changes and treatment completion by patients, due to BCG shortages or toxicities and adverse events as well as their impact on social activities, represent additional areas of potential improvement. Highly heterogeneous evidence for the effectiveness and safety of some treatments limits the comparability of results across studies. As a result, efforts are underway to standardize treatment schedules for BCG, but intravesical chemotherapy schedules remain unstandardized. In addition, risk-scoring models often perform unsatisfactorily due to significant differences between derivation and real-world cohorts. Reporting in clinical trials suffers from a lack of consistent outcomes reporting in bladder cancer clinical trials, paired with an under-representation of racial and ethnic minorities in many trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project

Author

Ahmad, Imran, Amer, Tarik, Andersen, Lars Dyrskjøt, Baker, Simon, Bhatt, Jaimin, Brown, Mary, Bryan, Richard, Catto, James W.F., Chahal, Rohit, Chapman, Alexander, Chaudhry, Altaf, DeSouza, John, Dimitropoulos, Konstantinos, Dreyer, Barend, Gourley, Charlie, Gray, Nurse Specialist Jennifer, Hamid, Sami, Hanchanale, Vishwanath, Harrison, Ewen, Hasan, Rami, Hendry, David, Hollins, Graham, Hussain, Syed A., Johnson, Mark, Johnston, Allan, Jones, Robert, Kandaswamy, Mr Gokul V., Kelly, John, Khan, Rehan, Kotwal, Sanjeev, Kumar, Pardeep, Kumar, Vivekanandan, Laing, Karina, Lord-McKenzie, Nurse Specialist Tanya, MacLennan, Steven, Makaroff, Lydia, Mitchell, Ian D.C., Morrison, David, Nair, Rajesh, Nandwani, Ghulam M., Norrie, John, Ramsey, Sara, Scowcroft, Henry, Sharpe, Clinical Nurse Specialist Claire, Simpson, Helen, Sridhar, Ashwin N., Thomas, Benjamin G., Thurairaja, Ramesh, Trail, Matthew, Hemelrijck, Mieke Van, Vasdev, Nikhil, and Mariappan, Paramananthan

Published
2021
Full Text
View/download PDF

39. What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?

Author

Dunsmore, Jennifer, Duncan, Eilidh, Mariappan, Paramananthan, de Bruin, Marijn, MacLennan, Sara, Dimitropoulos, Konstantinos, Kasivisvanathan, Veeru, Mostafid, Hugh, Briganti, Alberto, N'Dow, James, and MacLennan, Steven

Abstract

OBJECTIVE: To understand the barriers and facilitators to single instillation of intravesical chemotherapy (SI-IVC) use following resection of non-muscle-invasive bladder cancer (NMIBC) in Scotland and England using a behavioural theory-informed approach.MATERIALS AND METHODS: In a cross-sectional descriptive study of practices at seven hospitals, we investigated care pathways, policies, and interviewed 30 urology staff responsible for SI-IVC. We used the Theoretical Domains Framework (TDF) to organise our investigation and conducted deductive thematic analyses, while inductively coding emergent beliefs.RESULTS: Barriers to SI-IVC were present at different organisational levels and professional roles. In four hospitals there was a policy to not instil SI-IVC in theatre. Six hospitals' staff reported delays in MMC ordering and/or local storage. Lack of training, skills and perceived workload affected motivation. Facilitators included access to modern instilling devices (four hospitals) and incorporating reminders operation pro-forma (four hospitals). Performance targets (with audit and feedback) within a national governance framework was present in Scotland but not England. Differences in coordinated leadership, sharing best practices, and disliking being perceived as underperforming, were evident in Scotland.CONCLUSIONS: High-certainty evidence shows that SI-IVC such as Mitomycin C (MMC), following NMIBC resection reduces recurrences. This evidence underpins international guidance. Numbers of eligible patients receiving SI-IVC is variable indicating suboptimal practice. Improving SI-IVC adherence requires modifications to theatre instilling policies, delivery and storage of MMC, staff training, and documentation. Centralising care with bladder cancer expert leadership and best practices sharing, with performance targets, likely led to improvements in Scotland. National quality improvement, incorporating audit and feedback, with additional implementation strategies targeted to professional role could improve adherence and patient outcomes elsewhere. This process should be controlled to clarify implementation intervention effectiveness.

Published
2021
Full Text
View/download PDF

40. The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project

Author

Mariappan, Paramananthan, primary, Ahmad, Imran, additional, Amer, Tarik, additional, Andersen, Lars Dyrskjøt, additional, Baker, Simon, additional, Bhatt, Jaimin, additional, Brown, Mary, additional, Bryan, Richard, additional, Catto, James W.F., additional, Chahal, Rohit, additional, Chapman, Alexander, additional, Chaudhry, Altaf, additional, DeSouza, John, additional, Dimitropoulos, Konstantinos, additional, Dreyer, Barend, additional, Gourley, Charlie, additional, Gray, Nurse Specialist Jennifer, additional, Hamid, Sami, additional, Hanchanale, Vishwanath, additional, Harrison, Ewen, additional, Hasan, Rami, additional, Hendry, David, additional, Hollins, Graham, additional, Hussain, Syed A., additional, Johnson, Mark, additional, Johnston, Allan, additional, Jones, Robert, additional, Kandaswamy, Mr Gokul V., additional, Kelly, John, additional, Khan, Rehan, additional, Kotwal, Sanjeev, additional, Kumar, Pardeep, additional, Kumar, Vivekanandan, additional, Laing, Karina, additional, Lord-McKenzie, Nurse Specialist Tanya, additional, MacLennan, Steven, additional, Makaroff, Lydia, additional, Mitchell, Ian D.C., additional, Morrison, David, additional, Nair, Rajesh, additional, Nandwani, Ghulam M., additional, Norrie, John, additional, Ramsey, Sara, additional, Scowcroft, Henry, additional, Sharpe, Clinical Nurse Specialist Claire, additional, Simpson, Helen, additional, Sridhar, Ashwin N., additional, Thomas, Benjamin G., additional, Thurairaja, Ramesh, additional, Trail, Matthew, additional, Hemelrijck, Mieke Van, additional, and Vasdev, Nikhil, additional

Published
2021
Full Text
View/download PDF

41. The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Author

Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P., Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A., Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E., Downey, Alison P., Lal, Asim A, Antón-Juanilla, Marta, Clarke, Holly, Lau, David H. W., Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, MacLennan, Graeme, McGrath, John S., Kasivisvanathan, Veeru, Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed M, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kond?a, Andra?, Barcelos, André, Galosi, Andrea B, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, García de Jalón, Ángel, Desai, Ankit, Czech, Anna K, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Y?ld?r?m, As?f, Voulgaris, Athanasios M, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, ChiFai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Alonso, Cristina Plaza, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Lau, David Hua Wu, Hrouda, David, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Castillo, Elba Canelon, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Pita, Hernado Rios, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Fen Koo, Hui, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomakovi, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D, Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy YuenChun, Iacovou, John, Kelly, John, Selph, John P, Aning, Jonathan, Deeks, Jon, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Rivero, Marta Viridiana Muñoz, Pira, Matea, Tallè, Matteo, Liew, Matthew, Trail, Matthew, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akaln, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al?Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Manjavacas, Pablo Oteo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C, Osei?Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L, Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P, Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Inder, Shakeel Mohammud, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Kata, Slawomir Grzegorz, Lopes, Sofia Pinheiro, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Yan, Shahzad Sylvia, Drake, Tamsin, Toma, Tarq, Plo, Teresa Cabañuz, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Toma, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çakurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Cortes, Victor Parejo, Poves, Victoria Capapé, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Chin, Yew Fung, Filtekin, Yigit, Phan, Yih Chyn, Ibrahim, Youssed, Glaser, Zachary A, Adwin, Zainal, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli, Khadhouri, Sinan, Gallagher, Kevin M, Mackenzie, Kenneth R, Shah, Taimur T, Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F, Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P, Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A, Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E, Downey, Alison P, Lal, Asim Ahmed, Antón-Juanilla, Marta, Clarke, Holly, Hw Lau, David, Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, Maclennan, Graeme, Mcgrath, John S, Kasivisvanathan, Veeru, Khadhouri, Sinan [0000-0002-1836-8992], Moore, Sacha [0000-0002-0914-2051], Gómez Rivas, Juan [0000-0002-0556-3035], Olivier, Jonathan [0000-0002-5409-2911], Assmus, Mark A [0000-0003-3615-9251], Claps, Francesco [0000-0003-2812-5553], Nkwam, Nkwam [0000-0003-1086-6388], and Apollo - University of Cambridge Repository

Subjects
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, Male, =+16+years%2C+referred+to+secondary+care+with+suspected+urinary+tract+cancer%2E+Patients+with+a+known+or+previous+urological+malignancy+were+excluded%2E+We+estimated+the+prevalence+of+bladder+cancer%2C+UTUC%2C+renal+cancer+and+prostate+cancer%22">Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer, stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15, P < 0.001), male sex 1.30 (95% CI 1.14-1.50, P < 0.001), and smoking 2.70 (95% CI 2.30-3.18, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), bladder cancer, cancer prevalence, haematuria, hematuria, prostate cancer, renal cancer, upper tract urothelial cancer, urinary tract cancer, Adult, Aged, Female, Hematuria, Humans, Kidney Neoplasms, Middle Aged, Prospective Studies, Referral and Consultation, Ureteral Neoplasms, Urinary Bladder Neoplasms, Disease, urologic and male genital diseases, Prostate cancer, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, =+16+years%22">adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, Medicine, bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, education.field_of_study, and smoking 2.70 (95% CI 2.30-3.18, stratified by age, female genital diseases and pregnancy complications, renal cancer and prostate cancer, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, age 1.04 (95% CI 1.03-1.05 [stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were], UTUC (n = 128) 1.14% (95% CI 0.77-1.52), 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), visible haematuria 3.47 (95% CI 2.90-4.15, type of haematuria, P < 0.001), medicine.medical_specialty, Urology, Urinary system, Population, and countries. Results Of the 11 059 patients assessed for eligibility, Malignancy, smoking, UTUC, Internal medicine, sex, education, Bladder cancer, and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, business.industry, Cancer, Odds ratio, medicine.disease, male sex 1.30 (95% CI 1.14-1.50, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, hospitals, business
Abstract

Funder: Action Bladder Cancer UK, Funder: Rosetrees Trust; Id: http://dx.doi.org/10.13039/501100000833, Funder: Urology Care Foundation; Id: http://dx.doi.org/10.13039/100006280, OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. RESULTS: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). CONCLUSIONS: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.

Published
2021
Full Text
View/download PDF

46. What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?

Author

Dunsmore, Jennifer, primary, Duncan, Eilidh, additional, Mariappan, Paramananthan, additional, Bruin, Marijn, additional, MacLennan, Sara, additional, Dimitropoulos, Konstantinos, additional, Kasivisvanathan, Veeru, additional, Mostafid, Hugh, additional, Briganti, Alberto, additional, N’Dow, James, additional, and MacLennan, Steven, additional

Published
2021
Full Text
View/download PDF

48. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking

Author

Mariappan, Paramananthan, Finney, Steven M., Head, Elizabeth, Somani, Bhaskar K., Zachou, Alexandra, Smith, Gordon, Mishriki, Said F., NʼDow, James, and Grigor, Kenneth M.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results